Introduction to Ferroptosis in Glaucoma

Primary open-angle glaucoma (POAG) remains a leading cause of irreversible blindness worldwide. While clinicians traditionally focus on intraocular pressure, recent evidence suggests that molecular pathways like ferroptosis significantly drive the loss of retinal ganglion cells (RGCs). Ferroptosis is a unique form of iron-dependent, oxidative cell death characterized by lipid peroxidation. New research has now identified the specific role of NOX1 in glaucoma, providing a potential diagnostic biomarker and a target for neuroprotective therapy.

Identifying NOX1 as a Diagnostic Biomarker

Researchers recently utilized multiple machine learning algorithms and global GEO datasets to screen for critical ferroptosis-related genes. Through this bioinformatic exploration, they identified NOX1 as a high-value diagnostic biomarker for POAG progression. Notably, high expression levels of NOX1 correlate tightly with increased infiltration of CD8 and CD4 T cells within the ocular environment. This suggests that NOX1 might not only regulate cell death but also influence the local immune response. Consequently, detecting NOX1 levels could help clinicians identify patients at a higher risk for rapid disease advancement.

The Mechanistic Link: STAT3 and NOX1 in Glaucoma

Understanding the upstream regulation of NOX1 is vital for developing effective treatments. Mechanistically, the transcription factor STAT3 acts as a primary regulator of NOX1. Studies using dual luciferase assays and chromatin immunoprecipitation (ChIP) demonstrate that STAT3 binds directly to the NOX1 promoter region. Specifically, this binding occurs at the 419th to 429th bases upstream of the transcriptional start site. Therefore, when STAT3 is active, it upregulates NOX1 expression, which subsequently triggers the ferroptosis process in RGCs.

Clinical Implications for RGC Survival

Biological validation in H2O2-treated in vitro models has confirmed the impact of this pathway on cell viability. Silencing NOX1 effectively maintains RGC survival and inhibits the accumulation of reactive oxygen species (ROS). Furthermore, the inhibition of STAT3 reduces NOX1 expression, thereby preventing the structural mitochondrial damage typical of ferroptotic death. However, overexpressing NOX1 can reverse these protective effects, highlighting its central role in the disease process. These findings suggest that targeting the STAT3-NOX1 axis could offer a novel strategy to preserve vision in glaucoma patients.

Frequently Asked Questions

What is the role of NOX1 in glaucoma?

NOX1 acts as a critical regulator of ferroptosis, a type of cell death that causes the loss of retinal ganglion cells. It also serves as a diagnostic biomarker that correlates with immune cell infiltration.

How does STAT3 affect glaucoma progression?

STAT3 binds to the promoter of the NOX1 gene, increasing its expression. This transcriptional activation promotes ferroptosis, leading to the irreversible death of RGCs and the progression of glaucoma.

Can silencing NOX1 prevent vision loss?

Experimental models show that silencing NOX1 inhibits the ferroptosis process and maintains the survival of retinal ganglion cells, which may help slow down or prevent further vision loss.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice or a professional relationship. Always consult a qualified healthcare provider for diagnosis and treatment. Refer to the latest local and national guidelines for clinical practice.

References

1. Zong F et al. Ferroptosis regulator NOX1 acts a diagnostic biomarker and mediates disease progression with the transcriptional regulation of STAT3 in glaucoma. Indian J Ophthalmol. 2026 Mar 12. doi: 10.4103/IJO.IJO_1322_25. PMID: 41817565.


2. Zhou Y, Liu H. Ferroptosis and oxidative stress in glaucoma. Ferroptosis and Oxidative Stress. 2024;1(1):10-22.


3. Zhang C, Li H, Liu MG, et al. STAT3 activation protects retinal ganglion cell layer neurons in response to stress. Invest Ophthalmol Vis Sci. 2008;49(13):2433.